S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)

argenx (ARGX) Stock Forecast, Price & News

$388.70
-3.66 (-0.93%)
(As of 05/31/2023 ET)
Compare
Today's Range
$386.69
$396.21
50-Day Range
$356.85
$422.58
52-Week Range
$304.14
$423.99
Volume
252,684 shs
Average Volume
234,963 shs
Market Capitalization
$21.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$454.24

argenx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.94 Rating Score
Upside/​Downside
16.8% Upside
$455.67 Price Target
Short Interest
Bearish
1.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of argenx in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.33) to ($4.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

673rd out of 1,006 stocks

Biological Products, Except Diagnostic Industry

102nd out of 167 stocks


ARGX stock logo

About argenx (NASDAQ:ARGX) Stock

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
argenx SE (NASDAQ:ARGX) Short Interest Up 23.0% in May
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
argenx (NASDAQ:ARGX) Sees Strong Trading Volume
argenx SE (NASDAQ:ARGX) Short Interest Update
This Is What Whales Are Betting On argenx
argenx (NASDAQ:ARGX) Price Target Raised to $440.00
argenx (ARGX) Investor Presentation - Slideshow
argenx (NASDAQ:ARGX) Now Covered by Citigroup
argenx (NASDAQ:ARGX) Given "Outperform" Rating at Wedbush
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Company Calendar

Last Earnings
5/04/2023
Today
5/31/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$455.67
High Stock Price Forecast
$494.00
Low Stock Price Forecast
$425.00
Forecasted Upside/Downside
+16.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
19 Analysts

Profitability

Net Income
$-709,590,000.00
Pretax Margin
-89.41%

Debt

Sales & Book Value

Annual Sales
$445.27 million
Book Value
$50.79 per share

Miscellaneous

Free Float
54,325,000
Market Cap
$21.67 billion
Optionable
Optionable
Beta
0.75

Key Executives

  • Tim van Hauwermeiren
    Chief Executive Officer & Executive Director
  • Karen Massey
    Chief Operating Officer
  • Karl Gubitz
    Chief Financial Officer
  • Luc Truyen
    Chief Medical Officer
  • Peter Ulrichts
    Chief Scientific Officer













ARGX Stock - Frequently Asked Questions

Should I buy or sell argenx stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 hold rating and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price forecast for 2023?

19 Wall Street analysts have issued 12 month price targets for argenx's shares. Their ARGX share price forecasts range from $425.00 to $494.00. On average, they anticipate the company's stock price to reach $455.67 in the next year. This suggests a possible upside of 17.1% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2023?

argenx's stock was trading at $378.83 at the beginning of 2023. Since then, ARGX shares have increased by 2.7% and is now trading at $389.10.
View the best growth stocks for 2023 here
.

Are investors shorting argenx?

argenx saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,100,000 shares, an increase of 23.0% from the April 30th total of 894,500 shares. Based on an average daily volume of 243,000 shares, the short-interest ratio is currently 4.5 days.
View argenx's Short Interest
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($2.34) by $1.82. The firm earned $229.76 million during the quarter, compared to the consensus estimate of $191.24 million. argenx had a negative trailing twelve-month return on equity of 35.36% and a negative net margin of 79.45%.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.40%), Price T Rowe Associates Inc. MD (6.87%), Artisan Partners Limited Partnership (5.45%), Avoro Capital Advisors LLC (2.31%), Jennison Associates LLC (2.04%) and BlackRock Inc. (1.20%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $389.10.

How much money does argenx make?

argenx (NASDAQ:ARGX) has a market capitalization of $21.67 billion and generates $445.27 million in revenue each year. The company earns $-709,590,000.00 in net income (profit) each year or ($9.29) on an earnings per share basis.

How many employees does argenx have?

The company employs 650 workers across the globe.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -